
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. is recognized for its significant upside potential, as the current valuation reflects a balance between the company's inherent risks and its substantial growth opportunities. The company's diverse lines of business—Diagnostics, Medical Devices, and Digital Health—position it well for expansion, particularly with products like EsoGuard and the Veris Cancer Care Platform expected to gain traction in the 2025/26 timeframe. Additionally, the recent adjustments to price targets based on a net present value analysis indicate a favorable outlook for investors considering the company's early-stage commercialization efforts.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which was notably better than the consensus estimate range of $(0.13) to $(0.25). However, the company's declining performance in its flagship EsoGuard testing, with a decrease to 2,756 tests processed in Q2 from 3,034 in Q1 and 4,042 in Q4 of the previous year, raises concerns about its commercial viability and market demand. Additionally, significant risks surrounding liquidity, regulatory approvals, and competitive pressures further exacerbate the negative outlook for PAVmed's financial health and future growth potential.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares